The evolutionary epidemiology of multilocus drug resistance

Evolution

Volumn 66, Issue 5, 2012, Pages 1582-1597

  Day, Troy ^a   Gandon, Sylvain ^b  

^a QUEEN S UNIVERSITY   (Canada)

^b CENTRE D ECOLOGIE FONCTIONNELLE ET EVOLUTIVE   (France)

Author keywords

Antibiotic resistance; Compensatory mutation; Disease; Epistasis; Pathogen

Indexed keywords

ANTIBIOTIC RESISTANCE; DISEASE CONTROL; EPIDEMIOLOGY; EPISTASIS; EVOLUTIONARY BIOLOGY; MUTATION; PATHOGEN; PUBLIC HEALTH; RECOMBINATION;

ARTICLE; BIOLOGICAL MODEL; DRUG RESISTANCE; EPIDEMIOLOGY; GENETIC EPISTASIS; GENETIC RECOMBINATION; GENETIC SELECTION; GENETIC VARIABILITY; MOLECULAR EVOLUTION; MULTIFACTORIAL INHERITANCE;

DRUG RESISTANCE; EPIDEMIOLOGIC METHODS; EPISTASIS, GENETIC; EVOLUTION, MOLECULAR; GENETIC VARIATION; MODELS, GENETIC; MULTIFACTORIAL INHERITANCE; RECOMBINATION, GENETIC; SELECTION, GENETIC;

BACTERIA (MICROORGANISMS);

EID: 84860205114     PISSN: 00143820     EISSN: 15585646     Source Type: Journal    
DOI: 10.1111/j.1558-5646.2011.01533.x     Document Type: Article

References (50)

1. Althaus, C. L., and S. Bonhoeffer 2005. Stochastic interplay between mutation and recombination during the acquisition of drug resistance mutations in human immunodeficiency virus type 1. J. Virol. 79:13572-13578.
2. Anderson, R. M., and R. M. May 2001. Infectious diseases of humans. Oxford Univ. Press, Oxford, UK
3. Andersson, D. I., and D. Hughes 2010. Antibiotic resis tance and its cost: is it possible to reverse resistance Nat. Rev. Microbiol. 8:260-271.
4. Awadalla, P. 2003. The evolutionary genomics of pathogen recombination. Nat. Rev. Genet. 4:50-60.
5. Bergstrom, C. T., M. Lo, and M. Lipsitch 2004. Ecological theory suggests that antimicrobial cycling will not reduce antimicrobial resistance in hospitals. Proc. Natl. Acad. Sci. USA 101:13285-13290.
6. Bonhoeffer, S., M. Lipsitch, and B. R. Levin 1997. Evaluating treatment protocols to prevent antibiotic resistance. Proc. Natl. Acad. Sci. USA 94:12106-12111.
7. Bretscher, M. T., C. L. Althaus, V. Müller, and S. Bonhoeffer 2004. Recombination in HIV and the evolution of drug resistance: for better or for worse BioEssays 26:180-188.
8. Bürger, R. 2000. The mathematical theory of selection, recombination, and mutation. John Wiley and Sons, Chichester
9. Carvajal-Rodríguez, A., K. A. Crandall, and D. Posada 2007. Recombination favors the evolution of drug resistance in HIV-1 during antiretroviral therapy. Infect. Genet. Evol. 7:476-483.
10. Chait, R., A. Craney, and R. Kishony 2007. Antibiotic interactions that select against resistance. Nature 446:668-671.
11. Chou, H-H., H-C. Chiu, N. F. Delaney, D. Segrè, and C. J. Marx 2011. Diminishing returns epistasis among beneficial mutations decelerates adaptation. Science 332:1190-1192.
12. Crow, J. F., and M. Kimura 1970. An introduction to population genetics theory. Harper and Row, New York
13. Day, T., and S. Gandon 2006. Insights from Price's equation into evolutionary epidemiology. Pp. 23-44 in Disease evolution: models, concepts, and data analyses. American Mathematical Society, New York
14. Day, T., and S. Gandon 2007. Applying population-genetic models in theoretical evolutionary epidemiology. Ecol. Lett. 10:876-888.
15. Day, T., and S. R. Proulx 2004. A general theory for the evolutionary dynamics of virulence. Am. Nat. 163:E40-E63.
16. Fraser, C. 2005. HIV recombination: what is the impact on antiretroviral therapy J. R. Soc. Interface 2:489-503.
17. Gandon, S., and T. Day 2007. The evolutionary epidemiology of vaccination. J. R. Soc. Interface 4:803-817.
18. Gao, H., and M. W. Feldman 2009. Complementation and epistasis in virual coinfection dynamics. Genetics 182:251-263.
19. Hall, A. R., and R. C. MacLean 2011. Epistasis buffers the fitness effects of Rifampicin-resistance mutations in Pseudomonas aeruginosa. Evolution 65:2370-2379.
20. Hegreness, M., N. Shoresh, D. Damian, D. Hartl, and R. Kishony 2008. Accelerated evolution of resistance in multidrug environments. Proc. Natl. Acad Sci USA 105:13977-13981.
21. Hethcote, H. W. 2000. The mathematics of infectious diseases. SIAM Rev. 42:599-653.
22. Hill, W. G., and A. Robertson 1966. The effect of linkage on limits to artificial selection. Genet. Res. 8:269-294.
23. Hinkley, T., J. Martins, C. Chappey, M. Haddad, E. Stawiski, J. M. Whitcomb, C. J. Petropoulos, and S. Bonhoeffer 2011. A systems analysis of mutational effects in HIV-1 protease and reverse transcriptase. Nat. Genet. 43:487-490.
24. Khan, A. I., D. M. Dinh, D. Schneider, R. E. Lenski, and T. F. Cooper 2011. Negative epistasis between beneficial mutations in an evolving bacterial population. Science 332:1193-1196.
25. Kirkpatrick, M., T. Johnson, and N. Barton 2002. General models of multilocus evolution. Genetics 161:1727-1750.
26. Kouyos, R. D., D. Fouchet, and S. Bonhoeffer 2009. Recombination and drug resistance in HIV: population dynamics and stochasticity. Epidemics 1:58-69.
27. Kryazhimskiy, S., J. Dushoff, G. A. Bazykin, and J. B. Plotkin 2011. Prevalence of epistasis in the evolution of influenza A surface proteins. PLoS Genet. 7:e1001301.
28. Kvitek, D. J., and G. Sherlock 2011. Reciprocal sign epistasis between frequently experimentally evolved adaptive mutations causes a rugged fitness landscape. PLoS Genet. 7:e10002056.
29. Lenormand, T., and S. P. Otto 2002. The evolution of recombination in a heterogeneous environment. Genetics 156:423-438.
30. MacLean, R. C., A. R. Hall, G. G. Perron, and A. Buckling 2010. The population genetics of antibiotic resistance: integrating molecular mechanisms and treatment contexts. Nat. Rev. Genet. 11:405-414.
31. Maisnier-Patin, S., and D. I. Andersson 2004. Adaptation to the deleterious effects of antimicrobial drug resistance mutations by compensatory evolution. Res. Microbiol. 155:360-369.
32. Martin, G., S. F. Elena, and T. Lenormand 2007. Distributions of epistasis in microbes fit predictions from a fitness landscape model. Nat. Genet. 39:555-560.
33. Michel, J-B, P. J. Yeh, R. Chait, R. C. Moellering, Jr., and R. Kishony 2008. Drug interactions modulate the potential for evolution of resistance. Proc. Natl. Acad. Sci. USA 105:14918-1492.
34. Nowak, M. A., and R. M. May 1994. Superinfection and the evolution of parasite virulence. Proc. R. Soc. Lond. B 255:81-89.
35. Otto, S. P., and T. Day 2007. A biologist's guide to mathematical modeling. Princeton Univ. Press, Princeton, USA
36. Otto, S. P., and T. Lenormand 2002. Resolving the paradox of sex and recombination. Nat. Rev. Genet. 3:252-261.
37. Park, S-C., and J. Krug 2011. Bistability in two-locus models with selection, mutation, and recombination. J. Math. Biol. 62:763-788.
38. Poelwijk, F. J., D. J. Kiviet, D. M. Weinreich, and S. J. Tans 2007. Empirical fitness landscapes reveal accessible evolutionary paths. Nature 445:383-386.
39. Poelwijk, F. J., S. Tǎnase-Nicola, D. J. Kiviet, and S. J. Tans 2011. Reciprocal sign epistasis is a necessary condition for multi-peaked fitness landscapes. J. Theor. Biol. 272:141-144.
40. Rokyta, D. R., P. Joyce, S. B. Caudle, C. Miller, C. J. Beisel, and H. A. Wichman 2011. Epistasis between beneficial mutations and the phenotype-to-fitness map for a ssDNA virus. PLoS Genet. 7:e1002075.
41. Salverda, M. L. M., E. Dellus, F. A. Gorter, A. J. M. Debets, J. van der Oost, R. F. Hoekstra, D. S. Tawfik, and J. A. G. M. de Visser 2011. Initial mutations direct alternative pathways of protein evolution. PLoS Genet. 7:e1001321.
42. Simonsen, L., C. Viboud, B. T. Grenfell, J. Dushoff, L. Jennings, M. Smit, C. Macken, M. Hata, J. Gog, M.A. Miller, et al. 2007. The genesis and spread of reassortment human influenza A/H3N2 viruses conferring adamantane resistance. Mol. Biol. Evol. 24:1811-1820.
43. Slatkin, M. 1975. Gene flow and selection in a two locus system. Genetics 75:733-756.
44. Torella, J. P., R. Chait, and R. Kishony 2010. Optimal drug synergy in antimicrobial treatments. PloS Comput. Biol. 6:e1000796.
45. Trindade, S., A. Sousa, K. B. Xavier, F. Dionisio, M. G. Ferreira, and I. Gordo 2009. Positive epistasis drives the acquisition of multidrug resistance. PLoS Genet. 5:e1000578.
46. Weinreich, D. M., R. A. Watson, and L. Chao 2005. Perspective: sign epistasis and genetic constraint on evolutionary trajectories. Evolution 59:1165-1174.
47. Weinreich, D. M., N. F. Delaney, M. A. Depristo, and D. L. Hartl 2006. Darwinian evolution can follow only very few mutational paths to fitter proteins. Science 312:111-114.
48. Wiesch, P. S., J. Engelstädter, and S. Bonhoeffer 2010. Compensation of fitness costs and reversibility of antibiotic resistance mutations. Antimicro. Agents Chemother. 54:2085-2095.
49. Wijngaarden, P. J., F. van den Bosch, M. J. Jeger, and R. F. Hoekstra 2005. Adaptation to the cost of resistance: a model of compensation, recombination, and selection in a haploid organism. Proc. R. Soc. Lond. B 272:85-89.
50. Yeh, P. J., M. J. Hegreness, A. P. Aiden, and R. Kishony 2009. Drug interactions and the evolution of antibiotic resistance. Nat. Rev. Microbiol. 7:460-466.